Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients

Nephrology Dialysis Transplantation

Volumn 30, Issue 12, 2015, Pages 2068-2075

  Airy, Medha ^a   Mandayam, Sreedhar ^a   Mitani, Aya A ^b   Chang, Tara I ^c   Ding, Victoria Y ^c   Alan Brookhart, M ^d   Goldstein, Benjamin A ^e   Winkelmayer, Wolfgang C ^a,c  

^a Section of Nephrology   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d University of North Carolina at Chapel Hill   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cardiovascular; infection; intravenous iron; mortality; safety

Indexed keywords

FERRIC GLUCONATE; FERUMOXYTOL; IRON SACCHARATE; ANTIANEMIC AGENT; FERRIC ION; FERRIC OXIDE, SACCHARATED; MAGNETITE; SACCHARIC ACID;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG RESPONSE; DRUG SAFETY; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HEART INFARCTION; HEMODIALYSIS; HUMAN; INCIDENCE; INFECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PRIORITY JOURNAL; ANEMIA; COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RENAL INSUFFICIENCY, CHRONIC; STROKE; UNITED STATES;

ADMINISTRATION, INTRAVENOUS; AGED; ANEMIA; FEMALE; FERRIC COMPOUNDS; FERROSOFERRIC OXIDE; GLUCARIC ACID; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; STROKE; UNITED STATES;

EID: 84959421042     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv305     Document Type: Article

References (18)

1. Lu M, Cohen MH, Rieves D et al. FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol 2010; 85: 315-319
2. Spinowitz BS, Kausz AT, Baptista J et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008; 19: 1599-1605
3. Provenzano R, Schiller B, Rao M et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J AmSoc Nephrol 2009; 4: 386-393
4. Singh A, Patel T, Hertel J et al. Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis 2008; 52: 907-915
5. Fishbane S, Bolton WK, Winkelmayer WC et al. Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. Clin Nephrol 2012; 78: 181-188
6. Schiller B, Bhat P, Sharma A. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period. Clin Ther 2014; 36: 70-83
7. Slotki I, Cabantchik ZI. (May 21, 2015) The labile side of iron supplementation in CKD. J Am Soc Nephrol 2015; 26: 2612-2619
8. Winkelmayer WC, Chang TI, Mitani AA et al. Longer-Termoutcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: A quasi-experimental cohort study. Am J Kidney Dis 2015; 66: 106-113
9. Brookhart MA, Freburger JK, Ellis AR et al. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol 2013; 24: 1151-1158
10. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009; 28: 3083-3107
11. Montez-Rath ME, Winkelmayer WC, Desai M. Addressing missing data in clinical studies of kidney diseases. Clin J AmSoc Nephrol 2014; 9: 1328-1335
12. Sirken G, Raja R, Rizkala AR. Association of different intravenous iron preparations with risk of bacteremia in maintenance hemodialysis patients. Clin Nephrol 2006; 66: 348-356
13. Macdougall IC, Strauss WE, McLaughlin J et al. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol 2014; 9: 705-712
14. Kosch M, Bahner U, Bettger H et al. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant 2001; 16: 1239-1244
15. Sheashaa H, El-Husseini A, Sabry A et al. Parenteral iron therapy in treatment of anemia in end-stage renal disease patients: A comparative study between iron saccharate and gluconate. Nephron Clin Pract 2005; 99: c97-101
16. Anirban G, Kohli HS, Jha V et al. The comparative safety of various intravenous iron preparations in chronic kidney disease patients. Ren Fail 2008; 30: 629-638
17. United States Food and Drug Administration. Potential Signals of Serious Risks/New Safety Information Identified from the Adverse Event Reporting System (AERS) between April-June 2010. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrug Effects/ucm223734.htm (28 February 2011, date last accessed)
18. United States Food and Drug Administration. Letter from Robert Kane, MD, Deputy Division Director for Safety, Center for Drug Evaluation and Research to AMAG Pharmaceuticals Inc. http://www.accessdata.fda. gov/drugsatfda-docs/appletter/2010/022180s003, 022180s005ltr.pdf (28 February 2011, date last accessed)